Clinical trial Recruiting at 1 site Observational Ages 18 and up

Acute pancreatitis after percutaneous mechanical thrombectomy: a retrospective analysis

Official title: Retrospective Analysis of Acute Pancreatitis After Percutaneous Mechanical Thrombectomy In Treatment Of Thrombotic Disorders (The RATIO Study)

Run by RenJi Hospital · NCT07450898 · Data updated 2026-11-12

This project will look at adult medical records to see how often acute pancreatitis happens after percutaneous mechanical thrombectomy for thrombotic peripheral vascular disease.

Quick facts

Study typeObservational
Ages18 Years and up
SexAll
Enrollment10 (estimated)
SponsorRenJi Hospital
Academic / other
Locations1 site (Shanghai, Shanghai Municipality)
StatusRecruiting
StartedJanuary 1, 2016
Main results expectedMarch 31, 2026
Study endsDecember 31, 2026
Registry record updatedMarch 5, 2026
Trial IDNCT07450898 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (18+) who underwent percutaneous mechanical thrombectomy for thrombotic peripheral vascular disease at RenJi Hospital and developed acute pancreatitis within 14 days, and who can provide informed consent.

Probably not a fit

Patients whose pancreatitis has a confirmed alternative cause (such as gallstones, alcohol, or hyperlipidemia), patients treated outside RenJi Hospital, pediatric patients, or those unwilling/unable to participate are unlikely to benefit.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This retrospective observational project reviews adults treated with percutaneous mechanical thrombectomy at RenJi Hospital to identify cases of acute pancreatitis occurring within 14 days of the procedure. Researchers will determine incidence, grade severity, examine patient and procedural risk factors, and record clinical outcomes. The team will analyze procedural details (including rheolytic devices such as AngioJet), labs, imaging, and hospital course from chart review to develop a diagnosis and treatment pathway. The work uses existing records and informed consent where required for additional data collection.

Why it matters

Potential benefit: If successful, the findings could help clinicians recognize and treat post-thrombectomy pancreatitis sooner and reduce related complications.

How similar studies have gone: Only isolated case reports have described pancreatitis after mechanical thrombectomy, so no large systematic studies exist and this complication remains largely untested at scale.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients over 18 years old;
* Patients with thrombotic peripheral vascular diseases treated by percutaneous mechanical thrombectomy;
* Patients developed acute pancreatitis within 14 days after percutaneous mechanical thrombectomy;
* Patients with written informed consent.

Exclusion Criteria:

* Patients with acute pancreatitis attributed to other confirmed causes;
* Patients unable or unwilling to participate in the study.

Where it's running

  • Renji Hospital
    Shanghai, Shanghai Municipality, China
    Recruiting

Study contacts

  • Principal investigator: Qihong Ni — Department of Vascular Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University
  • Study coordinator: Qihong Ni
  • Email: niqihong1989@163.com
  • Phone: 15801900772

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.